ClinicalTrials.gg
RecruitingNCT07229937Updated Dec 12, 2025

A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia

A Phase 2 interventional study of HRS-1301 and HRS-1301 in Hyperlipidemia, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 1 of them phase 3. Hyperlipidemias · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
4th of 14
189 · median 78
Started
2025
with 4 others
Phase 2
4 of 14
2 open now
Registered
11th of 14
by date

Among the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., this one is the 4th largest by planned enrollment, is one of 5 that started in 2025, is one of 4 in phase 2, and was the 11th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

3 of the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The purpose of the study is to explore the reasonable dosage of HRS-1301 in participants with dyslipidemia. The efficacy and safety of HRS-1301 will be evaluated after 12-weeks treatment.

03

Conditions studied

  • Hyperlipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female ≥ 18 years old, who is able and willing to provide a written
  2. ≥ 18.0 kg/m2
  3. Clinically diagnosed with ASCVD and LDL-C ≥ 1.8 mmol/L OR, if no history of ASCVD, has intermediate to high risk of developing ASCVD and LDL-C ≥ 2.6 mmol/L
  4. Male and female subjects of and their partners must have no plans to donate sperm or become pregnant during the entire study period and for 2 weeks after the last dose, and agree to use methods as specified in the protocol

Exclusion criteria

Exclusion Criteria:

  1. TG > 5.6 mmol/L
  2. Diagnosed with homozygous familial hypercholesterolemia (HoFH)
  3. Acute ischemic ASCVD events within 12 months before screening, or during the screening and run-in phase
  4. Heart failure with (NYHA) Class III-IV
  5. Malignant tumors within 5 years
  6. Received or is regularly receiving LDL or plasma apheresis within 12 months before screening
  7. History or presence of severe gastrointestinal, hepatic, or renal diseases, or other known diseases that may interfere with drug absorption, distribution, metabolism, or excretion
  8. Uncontrolled diabetes mellitus and/or hypertension
  9. Has undergone transplantation of any vital organ, such as lung, liver, heart, bone marrow, or kidney
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
189 participants (estimated)

Study arms

  • Experimental
    HRS-1301 Group A

    Drug: HRS-1301

  • Experimental
    HRS-1301 Group B

    Drug: HRS-1301

  • Experimental
    HRS-1301 Group C

    Drug: HRS-1301

  • Experimental
    HRS-1301 Group D

    Drug: HRS-1301

  • Experimental
    HRS-1301 Group E

    Drug: Placebo

Interventions

  • HRS-1301 Dose 1,oral

  • HRS-1301 Dose 2,oral

  • HRS-1301 Dose 3,oral

  • HRS-1301 Dose 4,oral

  • DrugPlacebo

    Placebo,oral

06

What researchers measure

Primary outcomes

  1. Percentage change in LDL-C relative to baseline

    Time frame: at 12 weeks of treatment

Secondary outcomes

  1. Proportion of subjects achieving LDL-C goals

    Time frame: at 12 weeks of treatment

  2. Percentage change in TC relative to baseline;

    Time frame: at 12 weeks of treatment

  3. Percentage change in HDL-C relative to baseline;

    Time frame: at 12 weeks of treatment

  4. Percentage change in TG relative to baseline;

    Time frame: at 12 weeks of treatment

  5. Percentage change in non-HDL-C relative to baseline;

    Time frame: at 12 weeks of treatment

  6. Percentage change in ApoB relative to baseline;

    Time frame: at 12 weeks of treatment

  7. Percentage change in ApoA1 relative to baseline;

    Time frame: at 12 weeks of treatment;

  8. Percentage change in Lp(a) relative to baseline;

    Time frame: at 12 weeks of treatment;

  9. Percentage change in hsCRP relative to baseline;

    Time frame: at 12 weeks of treatment;

  10. Number of participants with one or more adverse events

    Time frame: during the study period;Approximately half a year

07

Study locations

1 of 1 sites recruiting
  • The 2nd Affiliated Hospital of Harbin
    Harbin, Heilongjiang 150086, China
    Recruiting
    • Bo Yu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Aug 2026, 9 months after the start.

Of 30 phase 2 interventional studies under Hyperlipidemias, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 17, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07229937
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Nov 25, 2025
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Dec 12, 2025

Study contacts

Miaomiao Shi
Contact
Miaomiao.shi@hengrui.com
18036617171

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-1301

Start the discussion